Men With an Improvement in Urinary Symptoms Have a Lower Risk of Mortality

The study analyzed data from the MTOPS trial, involving 3,046 men aged over 50 with moderate to severe lower urinary tract symptoms (LUTS). Participants were randomized to receive placebo, doxazosin, finasteride, or a combination of both drugs. Over an average follow-up of 6.1 years, 117 deaths were recorded. Results showed that each 1-point improvement in the American Urological Association Symptom Score (AUASS) was associated with a 4% reduction in the risk of death (HR 0.96, p=0.01), and a 5-point improvement corresponded to a 17% reduction (HR 0.83). This association held true across different treatment groups. The findings suggest that improving LUTS in men may lower mortality risk, indicating a potential shift in treatment focus towards symptom management.